Kornimate/medical-research-clean huggingface dataset:
diaphragmatic thickness and pulmonary function in parkinson's disease

Conditions: Parkinson's Disease and Parkinsonism

Summary: ultrasound can give important information about the morphology of the diaphragm and the amount of contraction. our aim, with the prediction that a restrictive pathology will occur in the pulmonary function with the addition of camptocormia in parkinson's patients; to compare respiratory functions in parkinson's patients with and without camptocormia, to investigate the correlation between ultrasonographically measured diaphragmatic thickness and pulmonary function test values.

respiratory complications are one of the most common causes of death in parkinson's patients. in parkinson's disease, abnormal flexion of the thoracolumbar spine of 45° or more, which is called camptocormia, increases during walking or standing and disappears completely in the supine position. the prevalence of camptocormia among parkinson's patients is about 7%. camptocormia in parkinson's disease is associated with significant disease disability, higher daily dopaminergic drug dosage, and cognitive impairment. parkinson's patients with camptocormia often complain of shortness of breath, attributed to reduced pulmonary capacity due to limited chest expansion. diaphragmatic dyskinesia in parkinson's patients may also lead to a restrictive deterioration in respiratory functions. diaphragmatic thickness indicates diaphragmatic contraction and is correlated with pft. our aim; it is a comparison of respiratory functions in parkinson's patients with and without camptocormia.

Eligibility criteria:
inclusion criteria: * being diagnosed with parkinson's * volunteer to participate in the study exclusion criteria: * being in contact with or suffering from covid-19 * having diseases that increase intra-abdominal pressure and venous insufficiency * having diseases that affect diaphragmatic motility * have had recent thoracic or abdominal surgery * having a parenchymal, pleural, or chest wall mass that may cause restriction on a recent chest x-ray or ct
the effect of mandala coloring on anxiety and mental fatigue in pregnant women diagnosed with threatened preterm labor

Conditions: Anxiety During Pregnancy; Mental Fatigue; Mandala

Summary: the research will be conducted in a pre-test-post-test control group randomized control design. the aim is to examine the effect of mandala work on anxiety and mental fatigue in pregnant women diagnosed with threatened preterm labor. hypotheses 1. mandala coloring work reduces the level of anxiety related to pregnancy in pregnant women diagnosed with threatened preterm labor. 2. mandala coloring work reduces the level of anxiety in pregnant women diagnosed with threatened preterm labor. 3. mandala coloring work reduces the level of mental fatigue in pregnant women diagnosed with threatened preterm labor. pregnant women who meet the inclusion criteria will be given general information about the research before randomization, their consent will be obtained and pre-test data will be collected. pregnant women whose pre-test data are collected will be assigned to the intervention and control groups using the simple randomization method. intervention group: participants in the intervention group will be given a set of colored markers and a mandala coloring page and will be asked to color them at any time of the day and in any way they want during their hospitalization. participants will be asked to take a picture of the mandala they colored and send it to the researcher after they are finished. participants will be reminded daily so that they do not forget to do the activity. research data will be collected a total of four times before randomization, on the 1st day, 2nd day and 3rd day after the mandala application was started. control group: no intervention other than routine care will be made to the control group of the study, and research data will be collected at simultaneous time intervals with the experimental group.


Eligibility criteria:
inclusion criteria: * pregnant women who can read and write turkish, * diagnosed with threatened preterm labor, * are between 32-36 weeks of gestation, * primiparous, * hospitalized, * open to communication (able to understand and answer questions) will be included in the sample. exclusion criteria: * pregnant women with a history of miscarriage or stillbirth, * those who voluntarily withdrew from the study, * those with a history of psychiatric illness (self-report), * those who do not have a physical disability that would prevent them from coloring mandalas will be excluded from the study.
an exploratory study of the effect of treatment interruption on safety of exenatide in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the primary purpose of this study is to assess the anti-exenatide-antibody response to exenatide re-exposure as measured by anti-exenatide antibodies and incidence of treatment-emergent allergy and hypersensitivity reactions following a period of treatment interruption, in patients previously exposed to exenatide.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes. * have been exposed to exenatide for at least 3 months in previous amylin/lilly studies h8o-mc-gwao, h8o-mc-gwap, h8o-mc-gwat, or h8o-mc-gwba. * have interrupted exenatide treatment for a period of at least 2 months. * hba1c of ≤10.5%. exclusion criteria: * have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. * have previously completed or withdrawn from this study. * have taken marketed exenatide (byetta) during the interim period between studies gwao, gwap, gwat, or gwba and the current study. * used drugs for weight loss (for example, xenical® \[orlistat\], meridia® \[sibutramine\], acutrim® \[phenylpropanolamine\], accomplia® \[rimonabant\], or similar over-the-counter medications) within 3 months of screening. * are currently treated with any of the following excluded medications: drugs that directly affect gastrointestinal motility, including, but not limited to: reglan® (metoclopramide), propulsid® (cisapride), and chronic macrolide antibiotics. * use insulin with daily dosage exceeding 1 u/kg.

Keywords: exenatide byetta antibodies amylin lilly
facilitation through aggrastat by dropping or shortening infusion line in patients with st-segment elevation myocardial infarction compared to or on top of prasugrel loading dose

Conditions: ST Segment Elevation Myocardial Infarction

Summary: this is a single-centre, open-label prospective randomized pharmacodynamic investigation of 2 antiplatelet regimens in patients undergoing coronary intervention for st segment elevation myocardial infarction(stemi): 1. tirofiban bolus only or bolus followed by 2 hour infusion on top of 600 mg clopidogrel or 60 mg prasugrel. 2. prasugrel given at 60 mg.

primary hypothesis: percentage ipa after 20umol/adp at 30' will be superior in the tirofiban arm (as aggregate) versus prasugrel alone arm percentage ipa at 30' after 20umol/adp 90%±15 and 80%±15 in the tirofiban and prasugrel alone arm, respectively. for a power of 90% and an alpha error set at 5%, 50 patients per group have to be recruited.

Eligibility criteria:
inclusion criteria: * chest pain for \>30 min with an electrocardiographic st-segment elevation more than 1 mm in two or more contiguous electrocardiogram (ecg) leads, or with a new left bundle-branch block, and admission either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia exclusion criteria: * administration of fibrinolytic or any gp iibiiia inhibitors for the treatment of current ami or within 1 month before history of bleeding diathesis * known sensitivity to abciximab, to any component of the product or to murine monoclonal antibodies * major surgery or trauma within 30 days * active bleeding * previous stroke in the last six months * oral anticoagulant therapy * pre-existing thrombocytopenia * vasculitis * hypertensive retinopathy * severe hepatic failure * severe renal failure requiring haemodialysis * documented allergy/intolerance or contraindication to clopidogrel or inability to assume clopidogrel on a consecutive daily basis for a minimum of 30 days, or to heparin or aspirin * uncontrolled hypertension (systolic or diastolic arterial pressure \>180 mmhg or 120, respectively, despite medical therapy) * limited life expectancy, e.g. neoplasms, others * inability to obtain informed consent

Keywords: prasugrel tirofiban clopidogrel glycoprotein iia/iiia inhibitors p2y12 blockers
first in man experience with a drug eluting stent in de novo coronary artery lesions

Conditions: Coronary Artery Disease

Summary: a prospective, single-treatment, multi centre clinical trial enrolling 30 patients in 2 centres in romania, with a clinical and angiographic follow-up at 4 and 9 months to determine the primary endpoint of late lumen loss and secondary endpoints. a subgroup of 15 patients will also undergo post implantation, 4 and 9 months ivus examinations. additional clinical follow-ups take place at 1 month and yearly up to three (3) years. the objective of this trial is to assess the safety and clinical performance of the orsiro drug eluting stent in patients with single de-novo coronary artery lesions.


Eligibility criteria:
inclusion criteria: 1. patient is ≥18 years old; 2. clinical evidence of ischemic heart disease and / or a positive functional study. documented stable angina pectoris (canadian cardiovascular society classification (ccs) 1, 2, 3 or 4 ), or documented silent ischemia; 3. single de novo lesion with ≥50% and \<90% stenosis in 1 coronary artery; exclusion criteria: 1. documented left ventricular ejection fraction (lvef) ≤30%; 2. unstable angina pectoris(braunwald class a i-iii) 3. three-vessel coronary artery disease 4. evidence of myocardial infarction within 72 hours prior to the index procedure; 5. known allergies to the following: acetylsalicylic acid (asa) (aspirin®), clopidogrel bisulfate (plavix®.) or ticlopidine (ticlid®.), heparin, contrast agent (that cannot be adequately premedicated), cobalt-chromium (cocr), poly-l-lactidic acid (plla), silicon carbide (asic:h) 6. a platelet count \ 700.000 cells/mm3 or a wbc \<3.000 cells/mm3; 7. acute or chronic renal dysfunction (serum creatinine \>2.0 mg/dl or \>150µmol/l); 8. total occlusion (timi 0 or 1); 9. target vessel has evidence of thrombus or is excessively tortuous that makes it unsuitable for proper stent delivery and deployment; 10. significant (\>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off; 11. heavily calcified lesion and/or calcified lesion which cannot be successfully predilated; 12. target lesion is located in or supplied by an arterial or venous bypass graft; 13. ostial target lesion (within 5.0mm of vessel origin); 14. target lesion involves a side branch \>2.0mm in diameter; 15. unprotected left main coronary artery disease (stenosis \>50%);
opsin receptors in melasma

Conditions: Melasma

Summary: melasma is a hyperpigmentation disorder that is probably exacerbated by visible light. opsin receptors (opn 1, 2, 3, 4 y 5) were described in the skin, being capable of activating melanogenesis induced by visible light. the aim of this study was to evaluate the expression of opn in melasma skin and its changes following treatment with uv-vis filter and 0.05% retinoic acid for 12 weeks.


Eligibility criteria:
inclusion criteria: * patients diagnosed with melasma, of 18 years of age and older, without previous treatment or photoprotection measures within the previous 4 weeks, who had melasma activity and severity index (masi) scores higher than 7 exclusion criteria: * pregnancy or nursing, menopause, coexistence of other pigmentation conditions, heat exposure, regular exercise, diet restriction, consumption of food supplements or any type of drugs (including anti-inflammatories and hormonal treatments) within the previous 2 months, and women who had given birth within 1 year
antihypertensive effect of simvastatin in hypertensive patients

Conditions: Hypertension

Summary: few trials have investigated the hypotensive effect of the statins. most were not specifically aimed at this pleiotropic effect or had methodological problems. the possible hypotensive effect may explain part of the favorable results of the statins use on cardiovascular prevention independently from its action on the cholesterol profile. the purpose of this study is to determine the effect of simvastatin on the blood pressure

this is a randomized double blind parallel clinical trial where hypertensive patients with controlled or uncontrolled blood pressure and without evidence of target-organ damage will be selected. subjects will receive simvastatin 40 mg once daily or placebo and a baseline and eight weeks abpm will performed. the main outcome will be the difference in systolic bp in the 24h-abpm.

Eligibility criteria:
inclusion criteria: * hypertensive patients with controlled or uncontrolled blood pressure exclusion criteria: * secondary causes of hypertension; * systolic blood pressure \>= 180 mmhg and/or diastolic blood pressure \>= 110 mmhg * complain of side effects related to statins * diabetes * established target-organ damage (myocardial infarction, stroke, angina, heart failure, peripheral vascular disease) * renal disease (creatinine \> 1,5 mgdl).
acute effects of caffeinated and decaffeinated coffee on bioelectrical impedance analysis

Conditions: Body Composition Measurement

Summary: this study investigates how caffeinated coffee, decaffeinated coffee, and water affect body composition, as measured by bia. participants were divided into three groups, consuming their respective beverages, with measurements taken over a 120-minute period. the study aimed to determine if caffeine or fluid intake is the primary driver of changes in body composition parameters.

this study aims to address these gaps by examining how caffeinated coffee, decaffeinated coffee, and water influence bia measurements at multiple intervals post-consumption (baseline, 30, 60, 90, and 120 minutes). by incorporating a controlled study design with separate water-only and caffeine-free groups, this methodology overcomes the limitations of previous studies that lacked comprehensive control conditions. by determining whether caffeine or fluid volume primarily drives changes in bia parameters and identifying the timing of these effects, this research seeks to improve the understanding of external factors affecting bia, providing valuable insights for accurate body composition assessments. participants were divided into three groups based on their average daily caffeine consumption: caffeinated coffee, decaffeinated coffee, and water. to standardize caffeine and fluid intake, filter coffee was chosen for its consistency in caffeine content and fluid volume. both caffeinated and decaffeinated arabic coffee were prepared using 11 g of coffee per 200 ml of water. the coffee was weighed using a precision balance and brewed with a filter coffee machine to ensure uniform preparation. participants were instructed to adhere to the following restrictions prior to the analysis day: a 12-hour fast, avoidance of excessive fluids, abstinence from caffeine-containing beverages, no showering or sauna use, no alcohol consumption for 48 hours, and no heavy exercise for 4-12 hours before the measurement. these restrictions minimized potential confounding effects on hydration or metabolic state, ensuring reliable bia measurements. the first bia measurements were taken before any beverage consumption. subsequently, participants consumed 200 ml of caffeinated coffee, decaffeinated coffee, or water, depending on their group. bia measurements were repeated at 30, 60, 90, and 120 minutes post-consumption.

Eligibility criteria:
inclusion criteria: * healthy adults aged ≥18 years. * bmi between 18.5 and 29.9 kg/m². * regular coffee consumers. * participants providing written informed consent. exclusion criteria: * individuals on medication or hormone therapy within the last 6 months. * medical conditions affecting caffeine metabolism (e.g., allergies or intolerances). * chronic or acute diseases. * significant appetite or eating disturbances in the past 6 months. * participants menstruating on the day of analysis.

Keywords: bioelectrical impedance analysis caffeine hydration body composition
gut microbiome and obesity

Conditions: Obesity, Childhood; Metabolic Syndrome

Summary: pediatric obesity is a risk factor for the onset of obesity in adulthood and is a risk factor for various chronic non-communicable diseases. metabolic syndrome (ms) is the name for a group of risk factors that increase cardiovascular risk and other health problems characterized by the presence of abdominal obesity, dyslipidemia, hyperglycaemia and high blood pressure. numerous preclinical and clinical data suggest a potential role of the intestinal microbiota in these diseaes. unfortunately, comparative studies of the gut microbiota are still scarce in pediatric subjects suffering from obesity than obesity complicated by ms. the aim is to study the metagenomics and metabolomics characteristics of the intestinal microbiota in obese children/adolescents with or without ms, that could provide useful data for innovative intervention strategies for these conditions.


Eligibility criteria:
inclusion criteria: * subjects aged between 10-16 years, * diagnosis of obesity or obesity complicated by metabolic syndrome * healthy controls exclusion criteria: * age at enrollment \ 16 years, * concomitant presence of chronic diseases, * neoplasms, * immunodeficiencies, * chronic infections, * autoimmune diseases, * chronic inflammatory bowel diseases, * celiac disease, -genetic-metabolic diseases, - * cystic fibrosis * chronic lung diseases, * malformations of the cardiovascular/respiratory/gastrointestinal system, * neuropsychiatric disorders * neurological pathologies, * assumption of antibiotics and/or pre/pro/synbiotics * onset of diarrhea or acute gastrointestinal disease during the 12 weeks prior to enrollment.
influence of tightly glucose control on hyperglycemic toxicity and protein catabolism in critically ill patients

Conditions: Critically Ill Patients

Summary: to compare the differences of urinary nitrogen excretion, nitrogen balance and clinical outcomes between tightly insulin therapy and conventional insulin therapy in the icu.

critical illness is associated with increased circulating concentrations of proinflammatory cytokines, such as tumor necrosis factor (tnf-α), interleukin (il)-1, and il-6 which may be important mediators of insulin resistance and results in hyperglycemia. altered glucose metabolism was caused by release of counter regulatory hormones such as glucagons; epinephrine and cortisol oppose the normal action of insulin, leading to an increase in skeletal muscle proteolysis. it did not know whether tightly glucose control had beneficial effect in urinary nitrogen excretion and nitrogen balance.

Eligibility criteria:
inclusion criteria: * patients admitted to the adult icu who had baseline blood glucose \> 180 mg/dl * expected to require treatment in the icu on 3 or more consecutive days. exclusion criteria: * pregnant patients * patients with chronic renal loss (chronic renal loss was defined as persistent acute renal failure, complete loss of kidney function \> 4 weeks)

Keywords: critical care, glycemic control, insulin, nitrogen balance
shanghai children and adolescent diabetes eye study

Conditions: Diabetes Mellitus; Eye Diseases

Summary: to compare the prevalence of eye disease between children and adolescents with diabetes mellitus and healthy people, and to analyze the related factors of eye diseases in diabetic patients.

a cohort study. from january 2018 to 2028, 300 cases of diabetic children in children's hospital of fudan university in shanghai will be selected as case group, and 300 healthy children without diabetes will be selected as the control group. the purpose of the study is to guide and regulate eye health screening of children and adolescents with diabetes in children's hospital of fudan university in shanghai, build up the ranks with the general practitioner as the backbone combined, and provide comprehensive, continuous, and dynamic information service to diabetic eye disease health management. we expect to reduce the prevalence rate of diabetic eye disease, blindness and visual impairment of dr, and improve diabetics consciousness of eye health maintenance, thus upgrading the level of eye disease prevention and treatment in shanghai.

Eligibility criteria:
inclusion criteria: * (1) provision of a written informed consent by a guardian; * (2) age over 5 years and less than 18 years; * (3) diagnosis of type 1 or type 2 diabetes based on the who diagnostic criteria for cases. exclusion criteria: * (1) eyelid diseases - eyelid entropion, eyelid ectropion, eyelid, ptosis, and palpebral dyskinesia; * (2) conjunctival diseases - pterygium and conjunctivitis; * (3) history of ocular surface chemical injury or use of eye drops with moisturizing artificial tears; * (4) history of eye surgery within 6 months or history of retinal laser photocoagulation; * (5) systemic diseases - sjogren syndrome, parkinson's disease, rheumatoid arthritis, grave 's disease, systemic lupus erythematosus, and others.
single dose liposomal amphotericin for asymptomatic cryptococcal antigenemia

Conditions: Cryptococcal Meningitis

Summary: this will be a randomized controlled trial of asymptomatic (cryptococcal antigen test)crag positive persons in uganda. patients will be randomized to receive preemptive treatment with 1 dose of liposomal amphotericin (10mg/kg) in addition to standard of care fluconazole therapy. how the enhanced antifungal therapy prevents progression to meningitis in the first 24-weeks and overall survival in those who receive the intervention compared with participants receiving fluconazole per world health organisation (who) and national standard of care therapy will be evaluated.


Eligibility criteria:
inclusion criteria: * hiv-1 infection * age \> or equal to15 years * ability and willingness to give informed consent. * plasma/serum cryptococcal antigen (crag)+ with a titer 1:160 or greater exclusion criteria: * cannot or unlikely to attend regular clinic visits * history of cryptococcal infection * symptomatic meningitis (confirmed by csf crag+) * \>14 days of fluconazole therapy * pregnancy (confirmed by urinary or serum pregnancy test) * current breastfeeding * known allergy to amphotericin
contactless detection of sleep apnea

Conditions: Sleep Apnea

Summary: in this study the inestigators aim to validate the performance of sleepiz one+ for sleep apnea detection during routine diagnostic sleep studies. patients who are prescribed polysomnography study will be asked to participate and undergo a simultaneous sleep recording with radar sensor-based device.


Eligibility criteria:
inclusion criteria: * age \>18years * ability and consent to undergo electrophysiological routine assessment * patients suspected to suffer from sleep apnea or any other sleep related disorder exclusion criteria: * previous enrollment into the current study, * enrollment of the investigator, his/her family members and other dependent persons * cardiac pacemaker or another implanted electrical device * women who are pregnant or breastfeeding * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, delirium etc. of the participant